Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit

The correct dose of therapeutic low molecular weight heparins (LMWHs) in patients with a body mass index £ 30 kg/m2 is uncertain. Literature and guidelines are not clear and consistent about the correct dose. DESIGN and METHODS In this review, an overview of the literature on therapeutic use of LMWHs in this population is provided. Sixteen pharmacokinetic and pharmacodynamic or clinical studies were included. RESULTS Based on these results, obese patients should receive therapeutic doses of LMWHs, based on their total body weight without a dose cap as recommended in the Summary of Product Characteristics. In patients with morbid obesity, anti-Xa level monitoring and subsequently an adjusted dosage on the base of supratherapeutic anti-Xa levels is recommended

Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit

The correct dose of therapeutic low molecular weight heparins (LMWHs) in patients with a body mass index £ 30 kg/m2 is uncertain. Literature and guidelines are not clear and consistent about the correct dose. DESIGN and METHODS In this review, an overview of the literature on therapeutic use of LMWHs in this population is provided. Sixteen pharmacokinetic and pharmacodynamic or clinical studies were included. RESULTS Based on these results, obese patients should receive therapeutic doses of LMWHs, based on their total body weight without a dose cap as recommended in the Summary of Product Characteristics. In patients with morbid obesity, anti-Xa level monitoring and subsequently an adjusted dosage on the base of supratherapeutic anti-Xa levels is recommended

Therapeutic use of low molecutar weight heparins in obese patients: Dosing based on body weight without cut-off timit

The correct dose of therapeutic low molecular weight heparins (LMWHs) in patients with a body mass index £ 30 kg/m2 is uncertain. Literature and guidelines are not clear and consistent about the correct dose. DESIGN and METHODS In this review, an overview of the literature on therapeutic use of LMWHs in this population is provided. Sixteen pharmacokinetic and pharmacodynamic or clinical studies were included. RESULTS Based on these results, obese patients should receive therapeutic doses of LMWHs, based on their total body weight without a dose cap as recommended in the Summary of Product Characteristics. In patients with morbid obesity, anti-Xa level monitoring and subsequently an adjusted dosage on the base of supratherapeutic anti-Xa levels is recommended